Benralizumab (eosinophilic granulomatosis with polyangiitis) – Addendum to Project A24-113

Report documents

1. Addendum

   Benralizumab (eosinophilic granulomatosis with polyangiitis) – Addendum to Project A24-113

   published on

   15.05.2025

   Document type

   PDF-Dokument, 291 kB, EN, PDF

   DOI-Link

   https://doi.org/10.60584/A25-49_en

   Download file : Addendum (PDF-Dokument, 291 kB, EN, PDF)

Additional information

Project details

Project no.

A25-49

Commission

Commission awarded on 08.04.2025 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A25-49_en

Connected Projects

1. Dossier assessment

   Benralizumab (eosinophilic granulomatosis with polyangiitis) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A24-113

   Last updated

   04.03.2025

   Status: Commission completed